
Bottega Veneta is betting on mycelium. Earlier this month, the Kering-owned brand released a limited collection of small leather goods swapping the bovine leather in its signature intrecciato weave for Ephea, a mycelium-based alternative by Italian biomaterials startup Sqim. The pieces are part of the fall 2026 men’s collection by creative director Louise Trotter.
For Kering, the six-piece collection is a vote of confidence for alternative materials. The luxury group took part in Sqim’s Series A funding round in 2024 and Balenciaga sent a coat made from Ephea down its FW22 runway, but this is the first time Bottega Veneta has used it. The collaboration comes after Ephea was incubated by Kering’s Material Innovation Lab in Milan, which identifies, evolves, and helps to operationalize hundreds of alternative materials, with the hope of embedding them into brand collections.
A win after false starts
In the early 2020s, mycelium-based alternatives to leather experienced something of a boom, attracting hundreds of millions in venture capital, boosted by glossy brand pilots and promises of commercial scale. Stella McCartney riffed on its signature Frayme bag with California material innovation startup Bolt Threads. Ganni followed, and even helped Bolt Threads launch the Greener Pastures Pledge, giving brands preferential access to its hero material — Mylo — if they vowed to phase out virgin leather. Then, in July 2021, former Hermès CEO Patrick Thomas joined the board of fellow Californian competitor Mycoworks, which released its first collaborative bag with Hermès later that year, and secured a $125 million cash injection shortly after. At the same time, Natural Fiber Welding inked partnerships with Stella McCartney, Ralph Lauren, MCM, and Alexander McQueen’s diffusion line MCQ to use its Mirum material.






